The prevalence of Api m 10 sensitization and the modification of immunotherapy in bee venom allergy
- PMID: 34658717
- PMCID: PMC8501423
- DOI: 10.5114/ada.2021.108922
The prevalence of Api m 10 sensitization and the modification of immunotherapy in bee venom allergy
Conflict of interest statement
The authors declare no conflict of interest.
References
-
- Bilò MB, Pravettoni V, Bignardi D, et al. Hymenoptera venom allergy: management of children and adults in clinical practice. J Investig Allergol Clin Immunol. 2019;29:180–205. - PubMed
-
- Biló MB. Anaphylaxis caused by Hymenoptera stings: from epidemiology to treatment. Allergy. 2011;66:35–7. - PubMed
-
- Müller UR. Bee venom allergy in beekeepers and their family members. Curr Opin Allergy Clin Immunol. 2005;5:343–7. - PubMed
-
- Golden DB, Moffitt J, Nicklas R, et al. Stinging insect hypersensitivity: a practice parameter update 2011. J Allergy Clin Immunol. 2011;127:852–4. - PubMed
-
- Blank S, Seismann H, Michel Y, et al. Api m 10, a genuine A. mellifera venom allergen, is clinically relevant but underrepresented in therapeutic extracts. Allergy. 2011;66:1322–9. - PubMed
LinkOut - more resources
Full Text Sources